Literature DB >> 31537692

Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations.

Simone Claudiani1,2, Jane F Apperley3,2, Afzal Khan2, Jamshid Khorashad2, Dragana Milojkovic3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31537692      PMCID： PMC7193492          DOI： 10.3324/haematol.2019.234179

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.

Authors:  Jun Imagawa; Hideo Tanaka; Masaya Okada; Hirohisa Nakamae; Masayuki Hino; Kazunori Murai; Yoji Ishida; Takashi Kumagai; Seiichi Sato; Kazuteru Ohashi; Hisashi Sakamaki; Hisashi Wakita; Nobuhiko Uoshima; Yasunori Nakagawa; Yosuke Minami; Masahiro Ogasawara; Tomoharu Takeoka; Hiroshi Akasaka; Takahiko Utsumi; Naokuni Uike; Tsutomu Sato; Sachiko Ando; Kensuke Usuki; Satoshi Morita; Junichi Sakamoto; Shinya Kimura
Journal:  Lancet Haematol       Date:  2015-11-10       Impact factor: 18.959

2.  The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.

Authors:  Franck E Nicolini; Amr R Ibrahim; Simona Soverini; Giovanni Martinelli; Martin C Müller; Andreas Hochhaus; Inge H Dufva; Dong-Wook Kim; Jorge Cortes; Michael J Mauro; Charles Chuah; Hélène Labussière; Stéphane Morisset; Catherine Roche-Lestienne; Eric Lippert; Sandrine Hayette; Senaka Peter; Wei Zhou; Véronique Maguer-Satta; Mauricette Michallet; John Goldman; Jane F Apperley; François-Xavier Mahon; David Marin; Gabriel Etienne
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

Review 3.  BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

Authors:  Simona Soverini; Andreas Hochhaus; Franck E Nicolini; Franz Gruber; Thoralf Lange; Giuseppe Saglio; Fabrizio Pane; Martin C Müller; Thomas Ernst; Gianantonio Rosti; Kimmo Porkka; Michele Baccarani; Nicholas C P Cross; Giovanni Martinelli
Journal:  Blood       Date:  2011-05-11       Impact factor: 22.113

4.  Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Authors:  Jorge E Cortes; Dong-Wook Kim; Javier Pinilla-Ibarz; Philipp D le Coutre; Ronald Paquette; Charles Chuah; Franck E Nicolini; Jane F Apperley; H Jean Khoury; Moshe Talpaz; Daniel J DeAngelo; Elisabetta Abruzzese; Delphine Rea; Michele Baccarani; Martin C Müller; Carlo Gambacorti-Passerini; Stephanie Lustgarten; Victor M Rivera; Frank G Haluska; François Guilhot; Michael W Deininger; Andreas Hochhaus; Timothy P Hughes; Neil P Shah; Hagop M Kantarjian
Journal:  Blood       Date:  2018-03-22       Impact factor: 22.113

5.  Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.

Authors:  Martin C Müller; Jorge E Cortes; Dong-Wook Kim; Brian J Druker; Philipp Erben; Ricardo Pasquini; Susan Branford; Timothy P Hughes; Jerald P Radich; Lynn Ploughman; Jaydip Mukhopadhyay; Andreas Hochhaus
Journal:  Blood       Date:  2009-09-24       Impact factor: 22.113

Review 6.  Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.

Authors:  Jane F Apperley
Journal:  Lancet Oncol       Date:  2007-11       Impact factor: 41.316

7.  Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.

Authors:  Jamshid S Khorashad; Hugues de Lavallade; Jane F Apperley; Dragana Milojkovic; Alistair G Reid; Marco Bua; Richard Szydlo; Eduardo Olavarria; Jaspal Kaeda; John M Goldman; David Marin
Journal:  J Clin Oncol       Date:  2008-07-21       Impact factor: 44.544

8.  Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.

Authors:  Elias Jabbour; Daniel Jones; Hagop M Kantarjian; Susan O'Brien; Constantine Tam; Charles Koller; Jan A Burger; Gautam Borthakur; William G Wierda; Jorge Cortes
Journal:  Blood       Date:  2009-06-30       Impact factor: 22.113

9.  Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

Authors:  Delphine Rea; Franck E Nicolini; Michel Tulliez; François Guilhot; Joelle Guilhot; Agnès Guerci-Bresler; Martine Gardembas; Valérie Coiteux; Gaelle Guillerm; Laurence Legros; Gabriel Etienne; Jean-Michel Pignon; Bruno Villemagne; Martine Escoffre-Barbe; Jean-Christophe Ianotto; Aude Charbonnier; Hyacinthe Johnson-Ansah; Marie-Pierre Noel; Philippe Rousselot; François-Xavier Mahon
Journal:  Blood       Date:  2016-12-08       Impact factor: 22.113

Review 10.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113
View more
  1 in total

Review 1.  Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission.

Authors:  Ruth Stuckey; Juan Francisco López Rodríguez; María Teresa Gómez-Casares
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.075
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.